<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neural Regen Res</journal-id><journal-id journal-id-type="iso-abbrev">Neural Regen Res</journal-id><journal-id journal-id-type="publisher-id">NRR</journal-id><journal-title-group><journal-title>Neural Regeneration Research</journal-title></journal-title-group><issn pub-type="ppub">1673-5374</issn><issn pub-type="epub">1876-7958</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25206715</article-id><article-id pub-id-type="pmc">4146079</article-id><article-id pub-id-type="publisher-id">NRR-8-693</article-id><article-id pub-id-type="doi">10.3969/j.issn.1673-5374.2013.08.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neurodegenerative Disease and Neural Regeneration</subject></subj-group></article-categories><title-group><article-title>Neuroprotective effects of tadalafil on gerbil dopaminergic neurons following cerebral ischemia<xref ref-type="author-notes" rid="fn">&#x02606;</xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Kwang Taek</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="fn"/></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Kyung Jin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Han Sae</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ko</surname><given-names>Il Gyu</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Chang Ju</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Na</surname><given-names>Yong Gil</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Khae Hawn</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label><italic>Department of Urology, Gachon University Gil Medical Center, Gachon University, Incheon 405-760, Republic of Korea</italic></aff><aff id="aff2"><label>2</label><italic>Department of Physiology, College of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea</italic></aff><aff id="aff3"><label>3</label><italic>Department of Urology, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon 301-721, Republic of Korea</italic></aff><author-notes><fn id="fn"><p>Kwang Taek Kim&#x02606;, M.D., Associate professor.</p></fn><corresp id="cor1">
Corresponding author: Khae Hawn Kim, Associate professor, Department of Urology, Gachon University Gil Medical Center, Gachon University, 1198 Guwol-dong, Namdong-Gu, Incheon 405-760, Republic of Korea, <email xlink:href="kimcho99@gilhospital.com">kimcho99@gilhospital.com</email>. (NY20121205001/H)
</corresp><fn fn-type="con"><p><bold>Author contributions:</bold> Kwang Taek Kim and Kyung Jin Chung collected the data and wrote the manuscript. Han Sae Lee and Yong Gil Na conceived and designed this study. Il Gyu Ko and Chang Ju Kim conducted experiments, and collected and analyzed the data. Khae Hawn Kim provided technical support and authorized the manuscript. All authors approved the final version of the paper.</p></fn><fn fn-type="other"><p><bold>Author statements:</bold> The manuscript is original, has not been submitted to or is not under consideration by another publication, has not been previously published in any language or any form, including electronic, and contains no disclosure of confidential information or authorship/patent application/funding source disputations.</p></fn></author-notes><pub-date pub-type="ppub"><day>15</day><month>3</month><year>2013</year></pub-date><volume>8</volume><issue>8</issue><fpage>693</fpage><lpage>701</lpage><history><date date-type="received"><day>10</day><month>12</month><year>2012</year></date><date date-type="accepted"><day>30</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Neural Regeneration Research</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Impairment of dopamine function, which is known to have major effects on behaviors and cognition, is one of the main problems associated with cerebral ischemia. Tadalafil, a long-acting phosphodiesterase type-5 inhibitor, is known to ameliorate neurologic impairment induced by brain injury, but not in dopaminergic regions. We investigated the neuroprotective effects of treatment with tadalafil on cyclic guanosine monophosphate level and dopamine function following cerebral ischemia. Forty adult Mongolian gerbils were randomly and evenly divided into five groups (<italic>n</italic> = 8 in each group): Sham-operation group, cerebral ischemia-induced and 0, 0.1, 1, and 10 mg/kg tadalafil-treated groups, respectively. Tadalafil dissolved in distilled water was administered orally for 7 consecutive days, starting 1 day after surgery. Cyclic guanosine monophosphate assay and immunohistochemistry were performed for thyrosine hydroxylase expression and western blot analysis for dopamine D<sub>2</sub> receptor expression. A decrease in cyclic guanosine monophosphate level following cerebral ischemia was found with an increase in thyrosine hydroxylase activity and a decrease in dopamine D<sub>2</sub> receptor expression in the striatum and substantia nigra region. However, treatment with tadalafil increased cyclic guanosine monophosphate expression, suppressed thyrosine hydroxylase expression and increased dopamine D<sub>2</sub> receptor expression in the striatum and substantia nigra region in a dose-dependent manner. Tadalafil might ameliorate cerebral ischemia-induced dopaminergic neuron injury. Therefore, tadalafil has the potential as a new neuroprotective treatment strategy for cerebral ischemic injury.</p></abstract><kwd-group><kwd>neural regeneration</kwd><kwd>brain injury</kwd><kwd>cerebral ischemia</kwd><kwd>Tadalafil</kwd><kwd>phosphodiesterase type-5 inhibitor</kwd><kwd>dopamine</kwd><kwd>dopamine D<sub>2</sub> receptor</kwd><kwd>cyclic guanosine monophosphate</kwd><kwd>grants-supported paper</kwd><kwd>photographs-containing paper</kwd><kwd>neuroregneration</kwd></kwd-group></article-meta></front><body><boxed-text position="float"><p><bold>Research Highlights</bold></p><p>(1) A phosphodiesterase type-5 inhibitor tadalafil significantly increased cyclic guanosine monophosphate level, suppressed thyrosine hydroxylase expression and increased dopamine D<sub>2</sub> receptor expression in the striatum and substantia nigra region in a dose-dependent manner.</p><p>(2) Tadalafil has the potential as a new neuroprotective treatment strategy for cerebral ischemic injury.</p></boxed-text><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Ischemic brain damage shows many manifestations, from neonatal asphyxia to adult stroke. Cerebral ischemia due to neonatal asphyxia is a common cause of functional and neurological damage in the developing brain of neonates. On the other hand, adult stroke is the second most common cause of death in industrialized countries and it has a deeply negative social and economic impact on those who survived, 80% of which is composed of ischemic injury after occlusion of a major cerebral artery or its branches[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>]. Tissue damage following cerebral ischemia is caused by complex pathophysiological processes, such as membrane depolarization, inflammation, glutamate excitotoxicity, and overexpression of dopamine[<xref rid="ref4" ref-type="bibr">4</xref>]. Ischemic episodes induced injury to multiple brain regions, including substantia nigra, basal ganglia, striatum, and hippocampus results in cognitive impairments and neurological damage[<xref rid="ref5" ref-type="bibr">5</xref>]. Dopamine, a major catecholamine in the central nervous system, contributes to control of motor activity, behavior, and cognition, and its dysfunctions are involved in a variety of neurological disorders, such as Parkinson's disease[<xref rid="ref6" ref-type="bibr">6</xref>]. The main determinant of dopamine pathway is the dopamine receptors. Dopamine receptors are divided into two classes, D<sub>1</sub>-like (D<sub>1</sub>, D<sub>2</sub>) and D<sub>2</sub>-like (D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>) dopamine receptors. It has been shown that dopamine D<sub>2</sub>-like receptor is closely related to various neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and stroke[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>]. The nigro-striatal pathway, one of the major dopamine pathways, is associated with the expression of tyrosine hydroxylase-positive cells and it is closely influenced after focal ischemia[<xref rid="ref9" ref-type="bibr">9</xref>]. Thyrosin hydroxylase is the rate-limiting enzyme in the synthesis of catecholamine neurotransmitters, such as dopamine, epinephrine, and norepinephrine. More specifically, it converts L-tyrosine to L-dihydroxyphenylalanine, which is the rate-limiting step in the synthesis of dopamine[<xref rid="ref10" ref-type="bibr">10</xref>]. Therefore, thyrosin hydroxylase activity shows a progressive change following the alteration of dopaminergic neurons in the substantia nigra of patients[<xref rid="ref11" ref-type="bibr">11</xref>]. Immunohistochemistry for detection of thyrosin hydroxylase activity has been used as an important method for detection of injury or death of dopaminergic fibers and cell bodies[<xref rid="ref12" ref-type="bibr">12</xref>]. Tadalafil, a long-acting phosphodiesterase type-5 inhibitor, is a highly specific key modulator of intracellular cyclic guanosine monophosphate signaling pathways[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>]. Cyclic guanosine monophosphate also plays critical roles in modulation of brain functions, including neurogenesis, synaptic plasticity, and physiological modulation of neurotransmitters[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref>]. Cyclic guanosine monophosphate is down-regulated in both striatum and nucleus accumbens by dopamine loss after brain injury[<xref rid="ref18" ref-type="bibr">18</xref>], otherwise, elevated production of cyclic guanosine monophosphate inhibits apoptosis and repairs damage by stimulating neurotransmitters[<xref rid="ref19" ref-type="bibr">19</xref>]. Phosphodiesterase type-5 inhibitors have also been reported to regulate neurotransmitters, such as dopamine and 5-hydroxytryptamine, after hippocampal neurodegeneration by multiple mechanisms[<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref>].</p><p>Although the functional role of tadalafil has been dramatically revealed in various brain diseases, there have been no reports on its efficacy in alleviation of the effects related to dopamine and dopaminergic receptor after cerebral ischemic injury. Therefore, in the current study, we investigated the neuroprotective effects of tadalafil on dopaminergic alteration in the striatum and substantia nigra following cerebral ischemic injury.</p></sec><sec sec-type="results" id="sec1-2"><title>RESULTS</title><sec id="sec2-1"><title>Quantitative analysis of experimental animals</title><p>Forty adult male Mongolian gerbils were randomly divided into five groups (<italic>n</italic> = 8 in each group): sham-operation, cerebral ischemia-induced, 0.1, 1, 10 mg/kg tadalafil-treated groups, and gerbils in the latter three groups were orally administered tadalafil dissolved in distilled water following cerebral ischemia. All 40 gerbils were included in the final analysis. The study timeline is presented in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Study timeline for cerebral ischemia induction, sham-operation, tadalafil treatment and tissue preparation.</p></caption><graphic xlink:href="NRR-8-693-g001"/></fig></sec><sec id="sec2-2"><title>Effect of tadalafil on cyclic guanosine monophosphate level in the striatum and substantia nigra</title><p>Cyclic guanosine monophosphate level in the striatum and substantia nigra of gerbils was detected in each group (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="fig" rid="F2">Figure 2</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Effects of consecutive tadalafil treatment on cyclic guanosine monophosphate (cGMP) level, thyrosine hydroxylase (TH) activity and dopamine D<sub>2</sub> receptor expression in the stratum and substantia nigra following cerebral ischemia</p></caption><graphic xlink:href="NRR-8-693-g002"/></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p>Effects of treatment with tadalafil on cyclic guanosine monophosphate (cGMP) level in the striatum (A) and substantia nigra (B) following cerebral ischemia.</p><p>I: Sham-operation group; II: cerebral ischemia-induced group; III&#x02013;V: 0.1, 1, and 10 mg/kg tadalafil-treated groups, respectively. One-way analysis of variance followed by Duncan's <italic>post-hoc</italic> test was used in performance of statistical analysis, and the results are presented as mean &#x000b1; SEM of eight gerbils per group. Each experiment was performed in triplicate. <sup>a</sup><italic>P</italic> &#x0003c; 0.05, <italic>vs</italic>. sham-operation group; <sup>b</sup><italic>P</italic> &#x0003c; 0.05, <italic>vs</italic>. cerebral ischemia-induced group.</p></caption><graphic xlink:href="NRR-8-693-g003"/></fig><p>Cerebral ischemic injury led to a decrease in cyclic guanosine monophosphate level in the striatum and substantia nigra, whereas treatment with tadalafil significantly suppressed the decrease in cyclic guanosine monophosphate level in a dose-dependent manner (<italic>P</italic> &#x0003c; 0.05).</p></sec><sec id="sec2-3"><title>Effect of tadalafil on thyrosin hydroxylase expression in the striatum and substantia nigra</title><p>The thyrosin hydroxylase expression in the striatum and substantia nigra was analyzed in each group (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="fig" rid="F3">Figure 3</xref>). Cerebral ischemic injury led to an increase of thyrosin hydroxylase expression in the striatum and substantia nigra, whereas treatment with tadalafil significantly suppressed the increase in thyrosin hydroxylase expression in a dose-dependent manner (<italic>P</italic> &#x0003c; 0.05).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Effects of treatment with tadalafil on thyroxine hydroxylase (TH) expression in the striatum (A) and substantia nigra (B) following cerebral ischemia.</p><p>Upper: Photomicrographs of TH expression in the striatum and substantia nigra. WB: Whole brain. (A1, B1) Sham-operation group; (A2, B2) cerebral ischemia-induced group; (A3&#x02013;A5, B3&#x02013;B5) 0.1, 1, and 10 mg/kg tadalafil-treated groups. The sections were stained for TH immunoreactivity (brown). Scale bars: 200 &#x003bc;m. Lower: Quantification of TH expression in each group. One-way analysis of variance followed by Duncan's <italic>post-hoc</italic> test was used in performance of statistical analysis, and the results are presented as mean &#x000b1; SEM of eight gerbils per group. Each experiment was performed in triplicate. <sup>a</sup><italic>P</italic> &#x0003c; 0.05,<italic>vs</italic>. sham-operation group; <sup>b</sup><italic>P</italic> &#x0003c; 0.05, <italic>vs</italic>. cerebral ischemia-induced group.</p></caption><graphic xlink:href="NRR-8-693-g004"/></fig></sec><sec id="sec2-4"><title>Effect of tadalafil on dopamine D<sub>2</sub> receptor expression in the striatum and substantia nigra as confirmed by western blot analysis</title><p>Mature dopamine D<sub>2</sub> receptor level was detected after the level of mature dopamine D<sub>2</sub> receptor (48&#x02013;51 kDa) expression in the striatum and substantia nigra of gerbils from the sham-operation group was designated as 1.00 (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="fig" rid="F4">Figure 4</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Effects of treatment with tadalafil on dopamine D<sub>2</sub> receptor expression in the striatum (A) and substantia nigra (B) following cerebral ischemia.</p><p>I: Sham-operation group; II: cerebral ischemia-induced group; III&#x02013;V: 0.1, 1, and 10 mg/kg tadalafil-treated group, respectively.</p><p>One-way analysis of variance followed by Duncan's <italic>post-hoc</italic> test was used in performance of statistical analysis, and the results are presented as mean &#x000b1; SEM of eight gerbils per group. The results are expressed as relative absorbance value of dopamine D<sub>2</sub> receptor/beta-actin normalized to sham-operation group. Each experiment was performed in triplicate. <sup>a</sup><italic>P</italic> &#x0003c; 0.05, <italic>vs</italic>. sham-operation group; <sup>b</sup><italic>P</italic> &#x0003c; 0.05, <italic>vs</italic>. cerebral ischemia- induced group.</p></caption><graphic xlink:href="NRR-8-693-g005"/></fig><p>Cerebral ischemic injury led to a decrease in expression of dopamine D<sub>2</sub> receptor in the striatum and substantia nigra, whereas treatment with tadalafil significantly suppressed the decrease in dopamine D<sub>2</sub> receptor in a dose-dependent manner (<italic>P</italic> &#x0003c; 0.05).</p></sec></sec><sec sec-type="discussion" id="sec1-3"><title>DISCUSSION</title><p>Dopamine appears to play an important role in mediation of cerebral ischemic brain injury[<xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref>]. Occurrence of ischemic episodes, such as those encountered in cerebral ischemia or anoxia, induces depletion of ATP level, leading to neuronal loss through mechanisms involving massive release of neurotransmitters, mainly dopamine and glutamate in the striatum[<xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref>]. Accordingly, increased extracellular dopamine concentration in cerebral ischemia was demonstrated using <italic>in vivo</italic> brain microdialysis[<xref rid="ref25" ref-type="bibr">25</xref><xref rid="ref26" ref-type="bibr">26</xref>]. It has also been demonstrated that ischemia-induced cell damage is accelerated by dopamine[<xref rid="ref27" ref-type="bibr">27</xref>] and extracellular levels of dopamine in the brain are related to the severity of cerebral ischemic injury[<xref rid="ref28" ref-type="bibr">28</xref>]. The loss of terminal dopaminergic fibers in the striatum appears to be more profoundly affected than the dopaminergic neuronal loss in the pars compacta of substantia nigra[<xref rid="ref29" ref-type="bibr">29</xref>]. In rodent models, thyrosin hydroxylase activity showed a progressive increase following the gain of dopaminergic neurons in the striatum and substantia nigra after cerebral ischemia[<xref rid="ref30" ref-type="bibr">30</xref>]. In this study, a significant increase in thyrosin hydroxylase-positive cells was also observed in the striatum and substantia nigra following induction of cerebral ischemia in gerbils.</p><p>Dopamine might enhance the striatal damage via dopamine D<sub>2</sub> receptor on ischemic neuronal cell[<xref rid="ref27" ref-type="bibr">27</xref>]. Dopamine D<sub>2</sub> receptor is a family of G protein-coupled receptors; its activation inhibits synaptogenesis in dopaminergic neurons through translational regulation of protein synthesis required for synapse formation[<xref rid="ref31" ref-type="bibr">31</xref>].</p><p>A decrease in expression of dopamine D<sub>2</sub> receptor was reported in the dorsal striatum, substantia nigra, and ventral tegmental area in an animal model of cerebral ischemia[<xref rid="ref32" ref-type="bibr">32</xref>]. Dopamine D<sub>2</sub> receptor also appears to be a key modulator of dopamine stimulation. The enhancement of dopamine D2 receptor function, induced by increased expression of Gi-&#x003b1; protein, accounts for the decrease in release of dopamine in the striatum of rats with cerebral ischemia[<xref rid="ref33" ref-type="bibr">33</xref>]. Several studies have reported that dopamine D<sub>2</sub> receptor stimulation may protect mesencephalic dopaminergic neurons from glutamate-and oxidative stress-induced cytotoxicity[<xref rid="ref34" ref-type="bibr">34</xref>] and cultured cortical neurons from glutamate-induced cytotoxicity[<xref rid="ref35" ref-type="bibr">35</xref>]. Dopamine D<sub>2</sub> receptor agonists are known to protect against ischemia-induced hippocampal neurodegeneration in global cerebral ischemia[<xref rid="ref32" ref-type="bibr">32</xref><xref rid="ref33" ref-type="bibr">33</xref><xref rid="ref34" ref-type="bibr">34</xref><xref rid="ref35" ref-type="bibr">35</xref><xref rid="ref36" ref-type="bibr">36</xref>]. On the other hand, chronic oral administration of a specific antagonist of dopamine D<sub>2</sub> receptor to rats and mice triggers decrement of the size of the axonal arbor of substantia nigra, pars compacta dopaminergic neurons in the striatum[<xref rid="ref37" ref-type="bibr">37</xref>]. Results of our study also showed significantly decreased expression of dopamine D<sub>2</sub> receptor in the striatum and substantia nigra following cerebral ischemia, indicating that cerebral ischemia suppressed dopamine D<sub>2</sub> receptor expression in the striatum and substantia nigra.</p><p>Tadalafil, phosphodiesterase type-5 inhibitor, has been widely used in treatment of erectile dysfunction, and has also been used therapeutically for men with erectile dysfunction in various brain disorders[<xref rid="ref38" ref-type="bibr">38</xref>]. Furthermore, it has been reported to be effective in treatment of an increasing number of various diseases, such as chronic obstructive pulmonary disease, hypertension, and coronary heart disease[<xref rid="ref39" ref-type="bibr">39</xref>]. For example, sildenafil citrate, a potent phosphodiesterase type-5 inhibitor, protected against ischemia/reperfusion-induced cardiac injury in adult rabbits[<xref rid="ref40" ref-type="bibr">40</xref>]. Production of cyclic guanosine monophosphate occurs in response to nitric oxide and natriuretic peptides. Cyclic guanosine monophosphate is a key regulator of cell proliferation, differentiation, and apoptosis, and it plays an important role in many pathophysiological processes, including synaptic plasticity, angiogenesis, inflammation, and cardiac hypertrophy[<xref rid="ref19" ref-type="bibr">19</xref>]. A possible neuroprotective effect is also suggested. The neuroprotective effect of phosphodiesterase type-5 inhibitors has been attributed to a decrease of cerebral metabolic rate, the retardation of the rate of high-energy phosphate depletion, and the promotion of post-ischemic metabolic recovery[<xref rid="ref41" ref-type="bibr">41</xref><xref rid="ref42" ref-type="bibr">42</xref>]. In addition, although it is still obscure, phosphodiesterase type-5 inhibitors modulate neurotransmitters such as glutamate, dopamine, and serotonin after cerebral injury[<xref rid="ref14" ref-type="bibr">14</xref>]. Tadalafil can cross the blood-brain barrier and induce significant improvement of learning/memory through modulation of the glutamate-nitric oxide-cyclic guanosine monophosphate signal transduction pathway. In these effects, signaling has been shown to play an important role in modulation of ion channels, synaptic transmission, and neurotransmitters[<xref rid="ref43" ref-type="bibr">43</xref><xref rid="ref44" ref-type="bibr">44</xref><xref rid="ref45" ref-type="bibr">45</xref>]. Elevated cyclic guanosine monophosphate modulates excessive neurotransmitters, and promotes blood overflowing in the brain. Nitric oxide enhances angiogenesis via synthesis of vascular endothelial growth factor and cyclic guanosine monophosphate after stroke in the rat. Sildenafil and an analog of cyclic guanosine monophosphate also induced formation of capillary-like tubes and these findings suggest that exogenous nitric oxide enhances angiogenesis in ischemic brain, which is mediated by the nitric oxide-cyclic guanosine monophosphate pathway[<xref rid="ref14" ref-type="bibr">14</xref>]. In this study, using enzyme immunoassay, we evaluated the effect of tadalafil on cerebral ischemia-induced cyclic guanosine monophosphate alteration, and observed a decrease in cyclic guanosine monophosphate level after transient cerebral ischemia.</p><p>We demonstrated that treatment with tadalafil significantly increased cyclic guanosine monophosphate level, suppressed thyrosin hydroxylase expression, and increased cerebral ischemia-induced expression of dopamine D<sub>2</sub> receptor in the striatum and substantia nigra in a dose-dependent manner.</p><p>Results from this study suggest that tadalafil treatment can suppress cerebral ischemia-induced excessive dopamine expression in the striatum and substantia nigra. These results also indicate that treatment with phosphodiesterase type-5 inhibitors promotes neurological function recovery of embolic stroke[<xref rid="ref46" ref-type="bibr">46</xref>].</p><p>Taken together, a phosphodiesterase type-5 inhibitor, tadalafil, can ameliorate cerebral ischemia-induced dopaminergic changes, thus, it might facilitate recovery after cerebral ischemic injury.</p></sec><sec sec-type="materials|methods" id="sec1-4"><title>MATERIALS AND METHODS</title><sec id="sec2-5"><title>Design</title><p>Randomized, controlled, animal experiments.</p></sec><sec id="sec2-6"><title>Time and setting</title><p>This study was performed in Gachon University of Medicine and Science and College of Medicine, Kyung Hee University, Republic of Korea from March 2010 to September 2011.</p></sec><sec id="sec2-7"><title>Materials</title><p>Forty adult male Mongolian gerbils, weighing 70 &#x000b1; 5 g, aged 15 weeks, obtained from a commercial breeder (Orient Co, Seoul, Korea), were used for the experiments. Each animal was housed under controlled temperature (22 &#x000b1; 2&#x000b0;C) and lighting (08:00&#x02013;20:00) conditions with food and water made available <italic>ad libitum</italic> during the entire period of study. All experimental procedures were performed in accordance with the animal care guidelines of the National Institutes of Health (NIH) and the Korean Academy of Medical Sciences (<ext-link ext-link-type="uri" xlink:href="http://www.kams.or.kr/">http://www.kams.or.kr/</ext-link>).</p></sec><sec id="sec2-8"><title>Methods</title><sec id="sec3-1"><title>Induction of transient global ischemia and tadalafil treatment</title><p>A previously described surgical procedure was used for induction of transient global ischemic injury of the cerebrum[<xref rid="ref21" ref-type="bibr">21</xref>]. In brief, gerbils were anesthetized with Zoletil 50<sup>&#x000ae;</sup> (10 mg/kg, intraperitoneal; Vibac Laboratories, Carros, France) and bilateral neck incisions were made. After neck dissection, both common carotid arteries were exposed and occluded with aneurysm clips for 5 minutes; the clips were then removed in order to restore cerebral blood flow. Body and rectal temperature was maintained at 36 &#x000b1; 0.5&#x000b0;C during surgery using a Homeothermic Blanket Control Unit (Harvard Apparatus, Massachusetts, MA, USA), and the gerbils were monitored for 2 hours to prevent hypothermia after the operation. For the sham-operation group, the same procedures, except for the common carotid artery occlusions, were performed according to the same timeline. Tadalafil-treated groups received tadalafil (Cialis<sup>&#x000ae;</sup>: Eli Lilly Co, Indianapolis, IN, USA) orally in distilled water once a day for 7 consecutive days, starting 1 day after surgery. The other groups received the same dose of distilled water only instead of tadalafil administration for the same period. The study timeline is presented in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p></sec><sec id="sec3-2"><title>Tissue preparation</title><p>The gerbils were sacrificed 1 day after the last administration of tadalafil or distilled water (8 days after the operation). The animals were anesthetized using Zoletil 50<sup>&#x000ae;</sup> (10 mg/kg, intraperitoneal; Vibac Laboratories), followed by transcardial perfusion with 50 mM PBS, and fixed with a freshly prepared solution consisting of 4% paraformaldehyde in 100 mM phosphate buffer (pH 7.4). Brains were harvested, post-fixed in the same fixative overnight, and transferred to 30% sucrose for cryoprotection. Coronal sections (40 &#x003bc;m thick) were made using a freezing microtome (Leica, Nussloch, Germany). Ten consecutive sections on average in the striatum and substantia nigra were collected from each gerbil, and 40&#x02013;50 sections were used.</p></sec><sec id="sec3-3"><title>Measurement of cyclic guanosine monophosphate production</title><p>In order to determine the effect of tadalafil on cyclic guanosine monophosphate production, cyclic guanosine monophosphate assay[<xref rid="ref47" ref-type="bibr">47</xref>] was performed according to the manufacturer's instructions using a commercially available cyclic guanosine monophosphate competitive enzyme immunoassay kit (Sapphire Bioscience Pty. Ltd., Redfern, Australia).</p></sec><sec id="sec3-4"><title>Thyrosin hydroxylase immunohistochemistry</title><p>Following incubation of free-floating tissue sections overnight with mouse anti-thyrosin hydroxylase antibody (1:1 000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4&#x000b0;C, the sections were incubated with biotinylated anti-mouse secondary antibody (1:200, Vector Laboratories, Burlingame, CA, USA) at 4&#x000b0;C for 1 hour. The sections were subsequently incubated with avidin-biotin-peroxidase complex (Vector Laboratories) for 1 hour at room temperature. Immunoreactivity was visualized by incubating the sections in a solution consisting of 0.05% 3,3-diaminobenzidine and 0.01% H<sub>2</sub>O<sub>2</sub> in 50 mM Tris-buffer (pH 7.6) for approximately 3 minutes. The sections were then washed three times with PBS and mounted onto gelatin-coated slides. The slides were air-dried overnight at room temperature, and cover slips were mounted using Permount<sup>&#x000ae;</sup> (Fisher Scientific, Hampton, NH, USA).</p></sec><sec id="sec3-5"><title>Western blot analysis for dopamine D2 receptor expression</title><p>Striatum and substantia nigra tissues were collected, and were immediately frozen at &#x02013;70&#x000b0;C. These tissues were homogenized on ice, and lysed in a lysis buffer containing 50 mM hydroxyethyl piperazine ethanesulfonic acid (pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM phenylmethyl sulfonylfluoride, 1 mM ethylene glycol tetraacetate, 1.5 mM MgCl<sub>2</sub>&#x000b7;6H<sub>2</sub>O, 1 mM sodium orthovanadate, and 100 mM sodium flouride. A Bio-Rad colorimetric protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA) was used for measurement of protein content. Protein (30 &#x003bc;g) was separated on sodium dodecyl sulphate-polyacrylamide gels and transferred onto a nitrocellulose membrane. Mouse anti-actin antibody (1:500; Santa Cruz Biotechnology) and mouse dopamine D<sub>2</sub> receptor antibody (1:1 000; Santa Cruz Biotechnology) were used as the primary antibodies for 24 hours at 4&#x000b0;C. Horseradish peroxidase-conjugated anti-mouse antibody for dopamine D2 receptor (1:2 000; Vector Laboratories) was used as the secondary antibody. All experimental procedures were performed in normal laboratory conditions and at room temperature; however, membrane transfers were performed at 4&#x000b0;C using a cold pack and pre-chilled buffer. Band detection was performed using an enhanced chemiluminescence detection kit (Santa Cruz Biotechnology).</p></sec><sec id="sec3-6"><title>Data analysis</title><p>For comparison of the relative expression of proteins, the detected bands were calculated densitometrically using Molecular Analyst<sup>&#x02122;</sup>, version 1.4.1 (Bio-Rad Laboratories). The numbers of thyrosin hydroxylase-positive cells in the substantia nigra were counted. The area of the striatum and substantia nigra on each section was measured using an Image-Pro<sup>&#x000ae;</sup> Plus computer-assisted image analysis system (Media Cyberbetics, Silver Spring, MD, USA) attached to a light microscope (Olympus, Tokyo, Japan). The numbers of thyrosin hydroxylase-positive cells in the substantia nigra were counted hemilaterally through a light microscope (Olympus). The density of thyrosin hydroxylase-immunoreactive fibers in the striatum was measured in 100 &#x003bc;m &#x000d7; 100 &#x003bc;m square images of the striatum using an image analyzer (Multiscan, Fullerton, CA, USA). To estimate the thyrosin hydroxylase staining density, the optical density was corrected for the nonspecific background density, which was measured in the completely denervated parts of the striatum. The density ratio of thyrosin hydroxylase-positive fibers in the striatum was calculated as follows: the absorbance in the lesion side divided by the absorbance in the intake side[<xref rid="ref48" ref-type="bibr">48</xref>].</p><p>All results were statistically analyzed using SPSS for Window, version 20.0 (SPSS, Chicago, IL, USA). One-way analysis of variance followed by Duncan's <italic>post-hoc</italic> test was used in performance of statistical analysis and the results are expressed as mean &#x000b1; SEM. Significance was set as <italic>P</italic> &#x0003c; 0.05.</p></sec></sec></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Funding:</bold> This study was supported by the Research Fund of Gachon University Gil Medical Center in 2011 and the National Research Foundation of Korea funded by the Korean Government, No. 2012R1A1A1013173.</p></fn><fn fn-type="conflict"><p><bold>Conflicts of interest:</bold> None declared.</p></fn><fn fn-type="other"><p><bold>Ethical approval:</bold> The experimental procedures were approved by the Institutional Animal Care and Use Committee of Gachon University of Medicine and Science and Kyung Hee University, Republic of Korea.</p></fn><fn fn-type="edited-by"><p>(Edited by Song LP)</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>[1]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>AR</given-names></name></person-group><article-title>Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly</article-title><source>Br J Pharmacol</source><year>2008</year><volume>153</volume><issue>Suppl 1</issue><fpage>S325</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">18059324</pub-id></element-citation></ref><ref id="ref2"><label>[2]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardlaw</surname><given-names>JM</given-names></name><name><surname>Murray</surname><given-names>V</given-names></name><name><surname>Berge</surname><given-names>E</given-names></name><etal/></person-group><article-title>Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis</article-title><source>Lancet</source><year>2012</year><volume>379</volume><issue>9834</issue><fpage>2364</fpage><lpage>2372</lpage><pub-id pub-id-type="pmid">22632907</pub-id></element-citation></ref><ref id="ref3"><label>[3]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Donnan</surname><given-names>GA</given-names></name></person-group><article-title>Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>20</issue><fpage>1914</fpage><lpage>1922</lpage><pub-id pub-id-type="pmid">22591297</pub-id></element-citation></ref><ref id="ref4"><label>[4]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name><name><surname>Moskowitz</surname><given-names>MA</given-names></name></person-group><article-title>Pathobiology of ischaemic stroke: an integrated view</article-title><source>Trends Neurosci</source><year>1999</year><volume>22</volume><issue>9</issue><fpage>391</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">10441299</pub-id></element-citation></ref><ref id="ref5"><label>[5]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>LW</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Pang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hypoxia-ischemia induced neurological dysfunction and brain injury in the neonatal rat</article-title><source>Behav Brain Res</source><year>2005</year><volume>165</volume><issue>1</issue><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">16140403</pub-id></element-citation></ref><ref id="ref6"><label>[6]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosboom</surname><given-names>JL</given-names></name><name><surname>Stoffers</surname><given-names>D</given-names></name><name><surname>Wolters</surname><given-names>E</given-names></name></person-group><article-title>Cognitive dysfunction and dementia in Parkinson's disease</article-title><source>J Neural Transm</source><year>2004</year><volume>111</volume><issue>10-11</issue><fpage>1303</fpage><lpage>1315</lpage><pub-id pub-id-type="pmid">15480840</pub-id></element-citation></ref><ref id="ref7"><label>[7]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piggott</surname><given-names>MA</given-names></name><name><surname>Owens</surname><given-names>J</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>J</given-names></name><etal/></person-group><article-title>Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease</article-title><source>J Chem Neuroanat</source><year>2003</year><volume>25</volume><issue>3</issue><fpage>161</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">12706204</pub-id></element-citation></ref><ref id="ref8"><label>[8]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantagrel</surname><given-names>S</given-names></name><name><surname>Gressens</surname><given-names>P</given-names></name><name><surname>Bodard</surname><given-names>S</given-names></name><etal/></person-group><article-title>mRNA D(2) dopaminergic receptor expression after hypoxia-ischemia in rat immature brain</article-title><source>Biol Neonate</source><year>2001</year><volume>80</volume><issue>1</issue><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11474153</pub-id></element-citation></ref><ref id="ref9"><label>[9]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>D</given-names></name><name><surname>Qi</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Improvement of focal ischemia-induced rat dopaminergic dysfunction by striatal transplantation of mouse embryonic stem cells</article-title><source>Neurosci Lett</source><year>2006</year><volume>407</volume><issue>1</issue><fpage>74</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">16959414</pub-id></element-citation></ref><ref id="ref10"><label>[10]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asanuma</surname><given-names>M</given-names></name><name><surname>Miyazaki</surname><given-names>I</given-names></name><name><surname>Ogawa</surname><given-names>N</given-names></name></person-group><article-title>Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease</article-title><source>Neurotox Res</source><year>2003</year><volume>5</volume><issue>3</issue><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">12835121</pub-id></element-citation></ref><ref id="ref11"><label>[11]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haavik</surname><given-names>J</given-names></name><name><surname>Toska</surname><given-names>K</given-names></name></person-group><article-title>Tyrosine hydroxylase and Parkinson's disease</article-title><source>Mol Neurobiol</source><year>1998</year><volume>16</volume><issue>3</issue><fpage>285</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">9626667</pub-id></element-citation></ref><ref id="ref12"><label>[12]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurley</surname><given-names>MJ</given-names></name><name><surname>Gerard</surname><given-names>DJ</given-names></name><name><surname>Jauniaux</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cultured human foetal cerebral cortex, transfected with tyrosine hydroxylase cDNA, as a source of neural transplant material</article-title><source>J Neural Transm</source><year>2001</year><volume>108</volume><issue>7</issue><fpage>781</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">11515744</pub-id></element-citation></ref><ref id="ref13"><label>[13]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybalkin</surname><given-names>SD</given-names></name><name><surname>Rybalkina</surname><given-names>IG</given-names></name><name><surname>Feil</surname><given-names>R</given-names></name><etal/></person-group><article-title>Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><issue>5</issue><fpage>3310</fpage><lpage>3317</lpage><pub-id pub-id-type="pmid">11723116</pub-id></element-citation></ref><ref id="ref14"><label>[14]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat</article-title><source>Circ Res</source><year>2003</year><volume>92</volume><issue>3</issue><fpage>308</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">12595343</pub-id></element-citation></ref><ref id="ref15"><label>[15]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prickaerts</surname><given-names>J</given-names></name><name><surname>Steinbusch</surname><given-names>HW</given-names></name><name><surname>Smits</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast</article-title><source>Eur J Pharmacol</source><year>1997</year><volume>337</volume><issue>2-3</issue><fpage>125</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">9430406</pub-id></element-citation></ref><ref id="ref16"><label>[16]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prickaerts</surname><given-names>J</given-names></name><name><surname>Sik</surname><given-names>A</given-names></name><name><surname>van Staveren</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Phosphodiesterase type 5 inhibition improves early memory consolidation of object information</article-title><source>Neurochem Int</source><year>2004</year><volume>45</volume><issue>6</issue><fpage>915</fpage><lpage>928</lpage><pub-id pub-id-type="pmid">15312986</pub-id></element-citation></ref><ref id="ref17"><label>[17]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CS</given-names></name><name><surname>Lin</surname><given-names>G</given-names></name><name><surname>Xin</surname><given-names>ZC</given-names></name><etal/></person-group><article-title>Expression, distribution and regulation of phosphodiesterase 5</article-title><source>Curr Pharm Des</source><year>2006</year><volume>12</volume><issue>27</issue><fpage>3439</fpage><lpage>3457</lpage><pub-id pub-id-type="pmid">17017938</pub-id></element-citation></ref><ref id="ref18"><label>[18]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgi</surname><given-names>M</given-names></name><name><surname>Melchiorri</surname><given-names>G</given-names></name><name><surname>Nuccetelli</surname><given-names>V</given-names></name><etal/></person-group><article-title>PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology</article-title><source>Neurobiol Dis</source><year>2011</year><volume>43</volume><issue>1</issue><fpage>293</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">21515371</pub-id></element-citation></ref><ref id="ref19"><label>[19]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilz</surname><given-names>RB</given-names></name><name><surname>Broderick</surname><given-names>KE</given-names></name></person-group><article-title>Role of cyclic GMP in gene regulation</article-title><source>Front Biosci</source><year>2005</year><volume>10</volume><fpage>1239</fpage><lpage>1268</lpage><pub-id pub-id-type="pmid">15769622</pub-id></element-citation></ref><ref id="ref20"><label>[20]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabayan</surname><given-names>B</given-names></name><name><surname>Zamiri</surname><given-names>N</given-names></name><name><surname>Farshchizarabi</surname><given-names>S</given-names></name></person-group><article-title>Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?</article-title><source>Int J Neurosci</source><year>2010</year><volume>120</volume><issue>12</issue><fpage>746</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">20942592</pub-id></element-citation></ref><ref id="ref21"><label>[21]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Treadmill exercise improves short-term memory by suppressing ischemia-induced apoptosis of neuronal cells in gerbils</article-title><source>Neurosci Lett</source><year>2004</year><volume>372</volume><issue>3</issue><fpage>256</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">15542251</pub-id></element-citation></ref><ref id="ref22"><label>[22]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banasiak</surname><given-names>KJ</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Haddad</surname><given-names>GG</given-names></name></person-group><article-title>Mechanisms underlying hypoxia-induced neuronal apoptosis</article-title><source>Prog Neurobiol</source><year>2000</year><volume>62</volume><issue>3</issue><fpage>215</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">10840148</pub-id></element-citation></ref><ref id="ref23"><label>[23]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuor</surname><given-names>UI</given-names></name><name><surname>Hudzik</surname><given-names>TJ</given-names></name><name><surname>Malisza</surname><given-names>K</given-names></name><etal/></person-group><article-title>Long-term deficits following cerebral hypoxia-ischemia in four-week-old rats: correspondence between behavioral, histological, and magnetic resonance imaging assessments</article-title><source>Exp Neurol</source><year>2001</year><volume>167</volume><issue>2</issue><fpage>272</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">11161615</pub-id></element-citation></ref><ref id="ref24"><label>[24]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orset</surname><given-names>C</given-names></name><name><surname>Parrot</surname><given-names>S</given-names></name><name><surname>Sauvinet</surname><given-names>V</given-names></name><etal/></person-group><article-title>Dopamine transporters are involved in the onset of hypoxia-induced dopamine efflux in striatum as revealed by <italic>in vivo</italic> microdialysis</article-title><source>Neurochem Int</source><year>2005</year><volume>46</volume><issue>8</issue><fpage>623</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">15863240</pub-id></element-citation></ref><ref id="ref25"><label>[25]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>A</given-names></name><name><surname>Koshimura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effects of transient forebrain ischemia and reperfusion on function of dopaminergic neurons and dopamine reuptake <italic>in vivo</italic> in rat striatum</article-title><source>Brain Res</source><year>1991</year><volume>561</volume><issue>1</issue><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">1797339</pub-id></element-citation></ref><ref id="ref26"><label>[26]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrot</surname><given-names>S</given-names></name><name><surname>Cottet-Emard</surname><given-names>JM</given-names></name><name><surname>Sauvinet</surname><given-names>V</given-names></name><etal/></person-group><article-title>Effects of acute hypoxic conditions on extracellular excitatory amino acids and dopamine in the striatum of freely-moving rats</article-title><source>Adv Exp Med Biol</source><year>2003</year><volume>536</volume><fpage>433</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">14635697</pub-id></element-citation></ref><ref id="ref27"><label>[27]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>N</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Mabe</surname><given-names>H</given-names></name><etal/></person-group><article-title>Dopamine has inhibitory and accelerating effects on ischemia-induced neuronal cell damage in the rat striatum</article-title><source>Brain Res Bull</source><year>1994</year><volume>33</volume><issue>3</issue><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">7904889</pub-id></element-citation></ref><ref id="ref28"><label>[28]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>DA</given-names></name><name><surname>Obrenovitch</surname><given-names>TP</given-names></name><name><surname>Johonson-Mora</surname><given-names>A</given-names></name><etal/></person-group><article-title>A previous potassium stimulation enhances the increases of striatal extracellular dopamine and 5-hydroxytryptamine during global ischaemia under simulated penumbral conditions</article-title><source>J Neurochem</source><year>1993</year><volume>61</volume><issue>6</issue><fpage>2233</fpage><lpage>2238</lpage><pub-id pub-id-type="pmid">7504088</pub-id></element-citation></ref><ref id="ref29"><label>[29]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernheimer</surname><given-names>H</given-names></name><name><surname>Birkmayer</surname><given-names>W</given-names></name><name><surname>Hornykiewicz</surname><given-names>O</given-names></name><etal/></person-group><article-title>Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations</article-title><source>J Neurol Sci</source><year>1973</year><volume>20</volume><issue>4</issue><fpage>415</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">4272516</pub-id></element-citation></ref><ref id="ref30"><label>[30]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakowec</surname><given-names>MW</given-names></name><name><surname>Nixon</surname><given-names>K</given-names></name><name><surname>Hogg</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway</article-title><source>J Neurosci Res</source><year>2004</year><volume>76</volume><issue>4</issue><fpage>539</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">15114626</pub-id></element-citation></ref><ref id="ref31"><label>[31]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasano</surname><given-names>C</given-names></name><name><surname>Poirier</surname><given-names>A</given-names></name><name><surname>DesGroseillers</surname><given-names>L</given-names></name><etal/></person-group><article-title>Chronic activation of the D2 dopamine autoreceptor inhibits synaptogenesis in mesencephalic dopaminergic neurons <italic>in vitro</italic></article-title><source>Eur J Neurosci</source><year>2008</year><volume>28</volume><issue>8</issue><fpage>1480</fpage><lpage>1490</lpage><pub-id pub-id-type="pmid">18973573</pub-id></element-citation></ref><ref id="ref32"><label>[32]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>MJ</given-names></name><name><surname>Hicks</surname><given-names>CA</given-names></name><name><surname>Ward</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia</article-title><source>Eur J Pharmacol</source><year>1998</year><volume>352</volume><issue>1</issue><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">9718265</pub-id></element-citation></ref><ref id="ref33"><label>[33]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>O</given-names></name><name><surname>Yoshiyama</surname><given-names>M</given-names></name><name><surname>Namiki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Changes in dopaminergic and glutamatergic excitatory mechanisms of micturition reflex after middle cerebral artery occlusion in conscious rats</article-title><source>Exp Neurol</source><year>2002</year><volume>173</volume><issue>1</issue><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">11771945</pub-id></element-citation></ref><ref id="ref34"><label>[34]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>H</given-names></name><name><surname>Ibi</surname><given-names>M</given-names></name><name><surname>Kihara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress</article-title><source>Ann Neurol</source><year>1998</year><volume>44</volume><issue>1</issue><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">9667598</pub-id></element-citation></ref><ref id="ref35"><label>[35]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kihara</surname><given-names>T</given-names></name><name><surname>Shimohama</surname><given-names>S</given-names></name><name><surname>Sawada</surname><given-names>H</given-names></name><etal/></person-group><article-title>Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade</article-title><source>J Neurosci Res</source><year>2002</year><volume>70</volume><issue>3</issue><fpage>274</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">12391586</pub-id></element-citation></ref><ref id="ref36"><label>[36]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil</article-title><source>J Neurol Sci</source><year>1995</year><volume>129</volume><issue>1</issue><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">7751851</pub-id></element-citation></ref><ref id="ref37"><label>[37]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripanichkul</surname><given-names>W</given-names></name><name><surname>Stanic</surname><given-names>D</given-names></name><name><surname>Drago</surname><given-names>J</given-names></name><etal/></person-group><article-title>D2 Dopamine receptor blockade results in sprouting of DA axons in the intact animal but prevents sprouting following nigral lesions</article-title><source>Eur J Neurosci</source><year>2003</year><volume>17</volume><issue>5</issue><fpage>1033</fpage><lpage>1045</lpage><pub-id pub-id-type="pmid">12653979</pub-id></element-citation></ref><ref id="ref38"><label>[38]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raffaele</surname><given-names>R</given-names></name><name><surname>Vecchio</surname><given-names>I</given-names></name><name><surname>Giammusso</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease</article-title><source>Eur Urol</source><year>2002</year><volume>41</volume><issue>4</issue><fpage>382</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">12074807</pub-id></element-citation></ref><ref id="ref39"><label>[39]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Driel</surname><given-names>MF</given-names></name></person-group><article-title>Phosphodiesterase inhibitors: effectiveness and new applications</article-title><source>Ned Tijdschr Geneeskd</source><year>2006</year><volume>150</volume><issue>29</issue><fpage>1613</fpage><lpage>1616</lpage><pub-id pub-id-type="pmid">16901064</pub-id></element-citation></ref><ref id="ref40"><label>[40]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ockaili</surname><given-names>R</given-names></name><name><surname>Salloum</surname><given-names>F</given-names></name><name><surname>Hawkins</surname><given-names>J</given-names></name><etal/></person-group><article-title>Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2002</year><volume>283</volume><issue>3</issue><fpage>H1263</fpage><lpage>1269</lpage><pub-id pub-id-type="pmid">12181158</pub-id></element-citation></ref><ref id="ref41"><label>[41]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arikan</surname><given-names>DC</given-names></name><name><surname>Bakan</surname><given-names>V</given-names></name><name><surname>Kurutas</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Protective effect of tadalafil on ischemia/reperfusion injury of rat ovary</article-title><source>J Pediatr Surg</source><year>2010</year><volume>45</volume><issue>11</issue><fpage>2203</fpage><lpage>2209</lpage><pub-id pub-id-type="pmid">21034945</pub-id></element-citation></ref><ref id="ref42"><label>[42]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozdegirmenci</surname><given-names>O</given-names></name><name><surname>Kucukozkan</surname><given-names>T</given-names></name><name><surname>Akdag</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effects of sildenafil and tadalafil on ischemia/reperfusion injury in fetal rat brain</article-title><source>J Matern Fetal Neonatal Med</source><year>2011</year><volume>24</volume><issue>2</issue><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">20540678</pub-id></element-citation></ref><ref id="ref43"><label>[43]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>RE</given-names></name></person-group><article-title>Cyclic GMP and ion channel regulation</article-title><source>Adv Second Messenger Phosphoprotein Res</source><year>1999</year><volume>33</volume><fpage>251</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">10218122</pub-id></element-citation></ref><ref id="ref44"><label>[44]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahern</surname><given-names>GP</given-names></name><name><surname>Klyachko</surname><given-names>VA</given-names></name><name><surname>Jackson</surname><given-names>MB</given-names></name></person-group><article-title>cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO</article-title><source>Trends Neurosci</source><year>2002</year><volume>25</volume><issue>10</issue><fpage>510</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">12220879</pub-id></element-citation></ref><ref id="ref45"><label>[45]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Klyachko</surname><given-names>V</given-names></name><name><surname>Jackson</surname><given-names>MB</given-names></name></person-group><article-title>Blockade of phosphodiesterase Type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release</article-title><source>J Physiol</source><year>2007</year><volume>584</volume><issue>Pt 1</issue><fpage>137</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">17690141</pub-id></element-citation></ref><ref id="ref46"><label>[46]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke</article-title><source>Brain Res</source><year>2006</year><volume>1118</volume><issue>1</issue><fpage>192</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">16959227</pub-id></element-citation></ref><ref id="ref47"><label>[47]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>IG</given-names></name><name><surname>Shin</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils</article-title><source>Pharmacol Biochem Behav</source><year>2009</year><volume>91</volume><issue>4</issue><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">19010346</pub-id></element-citation></ref><ref id="ref48"><label>[48]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Heo</surname><given-names>HI</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Treadmill exercise and methylphenidate ameliorate symptoms of attention deficit/hyperactivity disorder through enhancing dopamine synthesis and brain-derived neurotrophic factor expression in spontaneous hypertensive rats</article-title><source>Neurosci Lett</source><year>2011</year><volume>504</volume><issue>1</issue><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">21907264</pub-id></element-citation></ref></ref-list></back></article>